Halopropane

Halopropane (synonym FHD-3, trade name Tebron) is a halocarbon drug which was investigated as an inhalational anesthetic but was never marketed.[1] Its clinical development was terminated due to a high incidence of cardiac arrhythmias in patients, similarly to the cases of teflurane and norflurane.[2][3][4]

Halopropane

Clinical data
Trade names	Tebron
ATC code	None
Identifiers
IUPAC name 3-Bromo-1,1,2,2-tetrafluoropropane
CAS Number	679-84-5
PubChem CID	69623
ChemSpider	62826
UNII	3DC4A5894W
Chemical and physical data
Formula	C3H3BrF4
Molar mass	194.955 g·mol^−1
3D model (JSmol)	Interactive image
SMILES C(C(C(F)F)(F)F)Br
InChI InChI=1S/C3H3BrF4/c4-1-3(7,8)2(5)6/h2H,1H2 Key:YVWGMAFXEJHFRO-UHFFFAOYSA-N

See also

• Aliflurane
• Roflurane
• Synthane

References

1. Webster NR, Galley HF (22 August 2013). Landmark Papers in Anaesthesia. OUP Oxford. pp. 70–. ISBN 978-0-19-163319-5.
2. Acta anaesthesiologica Belgica. Acta Medica Belgica. 1974.
3. Klein SL (1993). A glossary of anesthesia and related terminology. Springer-Verlag. ISBN 978-0-387-97831-4.
4. Catcott EJ, Smithcors JF (1973). Progress in canine practice. American Veterinary Publications.